BR112017011217A2 - impurezas de dna em uma composição compreendendo um vírion parvoviral - Google Patents

impurezas de dna em uma composição compreendendo um vírion parvoviral

Info

Publication number
BR112017011217A2
BR112017011217A2 BR112017011217-5A BR112017011217A BR112017011217A2 BR 112017011217 A2 BR112017011217 A2 BR 112017011217A2 BR 112017011217 A BR112017011217 A BR 112017011217A BR 112017011217 A2 BR112017011217 A2 BR 112017011217A2
Authority
BR
Brazil
Prior art keywords
composition
parvoviral
relates
present
dna impurities
Prior art date
Application number
BR112017011217-5A
Other languages
English (en)
Inventor
LUBELSKI Jacek
Theodorus Johannes Maria Christiann Hermens Wilhelmus
Original Assignee
Uniqure Ip B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52000715&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017011217(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Uniqure Ip B.V. filed Critical Uniqure Ip B.V.
Publication of BR112017011217A2 publication Critical patent/BR112017011217A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção se refere a impurezas de ácido nucleico em uma composição compreendendo um vetor parvoviral. em particular, a presente invenção mostra que impurezas de dna não são encapsuladas aleatoriamente dentro de um vírion parvoviral. a invenção se refere, portanto, a um método para identificar e quantificar uma impureza de ácido nucleico em uma composição compreendendo um vetor parvoviral. finalmente, a presente invenção se refere a um método para determinar se uma composição compreendendo um vetor parvoviral é considerada clinicamente pura.
BR112017011217-5A 2014-11-28 2015-11-27 impurezas de dna em uma composição compreendendo um vírion parvoviral BR112017011217A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14195464 2014-11-28
EP14195464.4 2014-11-28
PCT/EP2015/077882 WO2016083560A1 (en) 2014-11-28 2015-11-27 Dna impurities in a composition comprising a parvoviral virion

Publications (1)

Publication Number Publication Date
BR112017011217A2 true BR112017011217A2 (pt) 2018-02-06

Family

ID=52000715

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017011217-5A BR112017011217A2 (pt) 2014-11-28 2015-11-27 impurezas de dna em uma composição compreendendo um vírion parvoviral

Country Status (19)

Country Link
US (2) US11021762B2 (pt)
EP (3) EP3224376B2 (pt)
JP (1) JP6741345B2 (pt)
KR (1) KR102528156B1 (pt)
CN (1) CN107208142B (pt)
AU (1) AU2015352469B2 (pt)
BR (1) BR112017011217A2 (pt)
CA (1) CA2968622A1 (pt)
CY (1) CY1122223T1 (pt)
DK (2) DK3591070T3 (pt)
EA (1) EA035747B1 (pt)
ES (1) ES2751919T5 (pt)
FI (1) FI3224376T4 (pt)
HK (1) HK1244849B (pt)
HU (1) HUE046643T2 (pt)
PL (1) PL3224376T5 (pt)
PT (1) PT3224376T (pt)
SI (1) SI3224376T2 (pt)
WO (1) WO2016083560A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201703148TA (en) 2014-11-05 2017-05-30 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
CN114717264A (zh) 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
KR102584655B1 (ko) 2014-11-14 2023-10-06 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
CA2968622A1 (en) 2014-11-28 2016-06-02 Uniqure Ip B.V. Dna impurities in a composition comprising a parvoviral virion
EP3230441A4 (en) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
GB2536650A (en) 2015-03-24 2016-09-28 Augmedics Ltd Method and system for combining video-based and optic-based augmented reality in a near eye display
BR112018073384A2 (pt) 2016-05-18 2019-03-06 Voyager Therapeutics, Inc. polinucleotídeos moduladores
CN110913866A (zh) 2017-05-05 2020-03-24 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
US11980507B2 (en) 2018-05-02 2024-05-14 Augmedics Ltd. Registration of a fiducial marker for an augmented reality system
US11766296B2 (en) 2018-11-26 2023-09-26 Augmedics Ltd. Tracking system for image-guided surgery
US11980506B2 (en) 2019-07-29 2024-05-14 Augmedics Ltd. Fiducial marker
US11382712B2 (en) 2019-12-22 2022-07-12 Augmedics Ltd. Mirroring in image guided surgery
WO2022188797A1 (en) 2021-03-09 2022-09-15 Huigene Therapeutics Co., Ltd. Engineered crispr/cas13 system and uses thereof
US11896445B2 (en) 2021-07-07 2024-02-13 Augmedics Ltd. Iliac pin and adapter
WO2023283962A1 (en) 2021-07-16 2023-01-19 Huigene Therapeutics Co., Ltd. Modified aav capsid for gene therapy and methods thereof
CN117660534B (zh) * 2023-12-13 2024-05-07 广州派真生物技术有限公司 一种降低重组腺相关病毒中宿主细胞dna残留的辅助质粒及应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0562047A4 (en) * 1990-12-06 1995-11-02 Affymax Tech Nv Sequencing by hybridization of a target nucleic acid to a matrix of defined oligonucleotides
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
EP1222299A1 (en) 1999-10-01 2002-07-17 Genovo, Incorporated Production of recombinant aav using adenovirus comprising aav rep/cap genes
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
EP3235827B1 (en) 2003-06-19 2021-01-13 Genzyme Corporation Aav virions with decreased immunoreactivity and uses therefor
CN101018858A (zh) * 2004-06-01 2007-08-15 建新公司 防止aav载体聚集的组合物和方法
SI1945779T1 (sl) 2005-10-20 2013-07-31 Uniqure Ip B.V. Izboljĺ ani aav vektorji proizvedeni v celicah insekta
CA2655957C (en) 2006-06-21 2016-05-03 Amsterdam Molecular Therapeutics (Amt) B.V. Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav in insect cells
MX2009002741A (es) * 2006-09-15 2009-05-11 Medimmune Llc Lineas de celulas mdck que soportan el crecimiento viral para altos titulos y proceso de biorreactor que utiliza las mismas.
MX2010000944A (es) 2007-07-26 2010-08-31 Amsterdam Molecular Therapeutics Bv Vectores baculovirales que comprenden secuencias de codificacion repetida con deformaciones diferenciales en codones.
EP2250256B1 (en) 2008-02-19 2017-08-02 uniQure IP B.V. Optimisation of expression of parvoviral rep and cap proteins in insect cells
MX340102B (es) 2010-01-28 2016-06-24 The Children's Hospital Of Philadelphia * Una plataforma de fabricacion ajustable en escala, para la purificacion de vector viral y vectores virales asi purificados para el uso en terapia de genes.
EP3792348A3 (en) * 2010-03-11 2021-06-23 uniQure IP B.V. Mutated rep encoding sequences for use in aav production
KR101334072B1 (ko) * 2010-11-25 2013-11-29 한국표준과학연구원 핵산 정량 방법 및 키트
WO2013011611A1 (ja) 2011-07-19 2013-01-24 株式会社 日立ハイテクノロジーズ 核酸分析方法及び核酸分析装置
FR2986239A1 (fr) 2012-01-31 2013-08-02 Univ Strasbourg Biomarqueur pour les maladies inflammatoires pulmonaires chroniques
JP6093358B2 (ja) * 2012-07-06 2017-03-08 タカラバイオ株式会社 アデノ随伴ウイルスベクターの産生細胞
JP6392222B2 (ja) * 2012-07-24 2018-09-19 ナテラ， インコーポレイテッド 高度多重ｐｃｒ法および組成物
JP2016517278A (ja) 2013-03-15 2016-06-16 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ スタッファー／フィラーポリヌクレオチド配列を含むベクターおよびその使用方法
CA2968622A1 (en) 2014-11-28 2016-06-02 Uniqure Ip B.V. Dna impurities in a composition comprising a parvoviral virion

Also Published As

Publication number Publication date
CN107208142A (zh) 2017-09-26
AU2015352469B2 (en) 2021-09-16
SI3224376T1 (sl) 2020-01-31
HUE046643T2 (hu) 2021-11-29
HK1244849B (zh) 2020-04-09
US11021762B2 (en) 2021-06-01
US20210332447A1 (en) 2021-10-28
JP6741345B2 (ja) 2020-08-19
DK3224376T4 (da) 2023-05-30
SI3224376T2 (sl) 2023-07-31
EA035747B1 (ru) 2020-08-05
JP2017535278A (ja) 2017-11-30
ES2751919T3 (es) 2020-04-02
DK3591070T3 (da) 2023-01-30
EP3591070B1 (en) 2022-12-21
ES2751919T5 (es) 2023-10-04
KR20170081704A (ko) 2017-07-12
PT3224376T (pt) 2019-10-25
AU2015352469A1 (en) 2017-06-01
PL3224376T5 (pl) 2023-08-21
US20170321290A1 (en) 2017-11-09
KR102528156B1 (ko) 2023-05-03
EP4219742A1 (en) 2023-08-02
WO2016083560A1 (en) 2016-06-02
DK3224376T3 (da) 2019-09-30
EP3224376B2 (en) 2023-04-26
EP3591070A1 (en) 2020-01-08
PL3224376T3 (pl) 2020-03-31
CN107208142B (zh) 2024-03-26
EA201791184A1 (ru) 2017-09-29
CA2968622A1 (en) 2016-06-02
CY1122223T1 (el) 2020-11-25
EP3224376B1 (en) 2019-08-07
EP3224376A1 (en) 2017-10-04
FI3224376T4 (fi) 2023-08-31

Similar Documents

Publication Publication Date Title
BR112017011217A2 (pt) impurezas de dna em uma composição compreendendo um vírion parvoviral
MX2022007933A (es) Compuestos de polimetino y su uso como etiquetas fluorescentes.
EP4257596A3 (en) Coumarin compounds and their uses as fluorescent labels
CO2017011957A2 (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
IL252556A0 (en) Nucleic acid constructs for genome editing
DK3459315T3 (da) Fremgangsmåde til direkte adgang til drift med flere numerologier
MX2016007541A (es) Moléculas modificadas de ácido nucleico y usos de las mismas.
MX2015011435A (es) Amplificación de ácidos nucléicos.
GB2537077A (en) Methods for sequencing nucleic acids
WO2015196128A3 (en) Alternative nucleic acid molecules and uses thereof
WO2015196130A3 (en) Alternative nucleic acid molecules and uses thereof
IL246501B (en) [1,4]diazepine compounds as inhibitors of autotaxin (atx) and lysophosphatidic acid (lpa) formation
EP3741849A3 (en) Protease variants and polynucleotides encoding same
JP2014064590A5 (pt)
MX2017007731A (es) Composiciones de detergente, variantes de lipasa y polinucleotidos que codifican las mismas.
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
DK3242903T3 (da) Sammensætninger til at indføre nukleinsyre i celler
BR112017013394A2 (pt) fabricação de proteína
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
BR112013005412A2 (pt) método aparelho, meio de armazenamento legível por computador que possui uma ou mais sequências de uma ou mais instruções, produto de programa de computador
MX2017005219A (es) Composiciones de curado anaerobio que tienen esteres vinilicos novolac.
WO2014210199A3 (en) Methods of performing polymerase chain reaction and related uses thereof
WO2014145870A3 (en) Novel compositions, methods and kits for blood typing
MX2016006602A (es) Amplificacion de acidos nucleicos.
BR112017024855A2 (pt) métodos de produção de aldc

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.